Low-Level Endothelial TRAIL-Receptor Expression Obstructs the CNS-Delivery of Angiopep-2 Functionalised TRAIL-Receptor Agonists for the Treatment of Glioblastoma
Glioblastoma (GBM) is the most malignant and aggressive form of glioma and is associated with a poor survival rate. Latest generation Tumour Necrosis Factor Related Apoptosis-Inducing Ligand (TRAIL)-based therapeutics potently induce apoptosis in cancer cells, including GBM cells, by binding to deat...
Principais autores: | Nivetha Krishna Moorthy, Oliver Seifert, Stephan Eisler, Sara Weirich, Roland E. Kontermann, Markus Rehm, Gavin Fullstone |
---|---|
Formato: | Artigo |
Idioma: | English |
Publicado em: |
MDPI AG
2021-12-01
|
coleção: | Molecules |
Assuntos: | |
Acesso em linha: | https://www.mdpi.com/1420-3049/26/24/7582 |
Registros relacionados
-
Revealing Angiopep-2/LRP1 Molecular Interaction for Optimal Delivery to Glioblastoma (GBM)
por: Angela Costagliola di Polidoro, et al.
Publicado em: (2022-10-01) -
Specific anti‐glioma targeted‐delivery strategy of engineered small extracellular vesicles dual‐functionalised by Angiopep‐2 and TAT peptides
por: Zhanchi Zhu, et al.
Publicado em: (2022-08-01) -
An Angiopep2-PAPTP Construct Overcomes the Blood-Brain Barrier. New Perspectives against Brain Tumors
por: Sofia Parrasia, et al.
Publicado em: (2021-02-01) -
Development of Angiopep-2 targeted dendrimer-based nanotheranostic system for enhanced temozolomide delivery to glioblastoma multiforme
por: Ashish Kumar Parashar, et al.
Publicado em: (2025-02-01) -
Urban trails : a preliminary list of trails and sources/
por: 409605 Goodey, Brian
Publicado em: (1974)